Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol to prevent loss of kidney function in type 1 diabetes
2014-001786-26Phase 3Completed
- Sponsor
- Steno Diabetes Center
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of allopurinol in diabetes mellitus type 1 (T1D), diabetic glomerulosclerosis and hyperuricemia (2 arms), sponsored by Steno Diabetes Center. Primary endpoint: Change in albuminuria (urinary albumin excretion, UAE). Started Jun 2014; status: completed.
02
Drugs
allopurinol
03
Conditions
diabetes mellitus type 1 (T1D)diabetic glomerulosclerosishyperuricemia
Beyond the preview
Go deeper on 2014-001786-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001786-26.